{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:40:03Z","timestamp":1792744803610,"version":"4.5.0"},"reference-count":37,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100012150","name":"Shanghai Leading Academic Discipline Project","doi-asserted-by":"publisher","award":["LJ2024078"],"award-info":[{"award-number":["LJ2024078"]}],"id":[{"id":"10.13039\/501100012150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["24TS1415300"],"award-info":[{"award-number":["24TS1415300"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471976"],"award-info":[{"award-number":["82471976"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472039"],"award-info":[{"award-number":["82472039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92159203"],"award-info":[{"award-number":["92159203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The evaluation of treatment response in triple-negative breast cancer (TNBC) still primarily relies on tumor size and ex vivo analyses, which provide very limited information on how tumors dynamically respond during therapy. In fact, oxidative stress rapidly emerges early after drug treatment, while PD-L1 reflects an adaptive signal associated with tumors. However, these treatment-associated features are commonly assessed using static detection methods, thereby limiting longitudinal in vivo evaluation. To address this, we developed a theranostic nanoprobe named RAPP, which integrates DOX delivery, ROS-responsive near-infrared fluorescence (NIRF) imaging, and PD-L1-targeted magnetic resonance imaging (MRI). In this system, the fluorescence signal serves to report early oxidative stress in real time, while PD-L1 targeting contributes to tumor-directed MRI, enabling longitudinal assessment of both signals in a 4T1 TNBC model. During treatment, RAPP produced distinct changes in fluorescence and MR signals across different experimental groups, indicating the complementarity of these two imaging modalities in evaluating tumor response. Furthermore, DOX-loaded RAPP effectively inhibited tumor growth without exhibiting significant systemic toxicity. By integrating drug delivery with dual-modal imaging, RAPP offers a practical strategy for assessing tumor response in TNBC during treatment, rather than only after treatment completion.<\/jats:p>","DOI":"10.1021\/acssensors.6c03428","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:02:04Z","timestamp":1791583324000},"page":"9694-9705","source":"Crossref","is-referenced-by-count":0,"title":["PD-L1-Targeted and ROS-Responsive Nanoplatform for Simultaneous Chemotherapy and Dual-Modal Imaging of Treatment Response in Triple-Negative Breast Cancer"],"prefix":"10.1021","volume":"11","author":[{"given":"Jingjing","family":"Hu","sequence":"first","affiliation":[{"name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , , ,","place":["Shanghai, China, 200092"]},{"name":"Shanghai Jiao Tong University School of Medicine , , ,","place":["Shanghai, China, 200025"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunting","family":"Wang","sequence":"additional","affiliation":[{"name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , , ,","place":["Shanghai, China, 200092"]},{"name":"Shanghai University of Sport , ,","place":["Shanghai, China, 200438"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Chen","sequence":"additional","affiliation":[{"name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , , ,","place":["Shanghai, China, 200092"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiying","family":"Zhu","sequence":"additional","affiliation":[{"name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , , ,","place":["Shanghai, China, 200092"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , , ,","place":["Shanghai, China, 200092"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"Chen","sequence":"additional","affiliation":[{"name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , , ,","place":["Shanghai, China, 200092"]},{"name":"Shanghai University of Sport , ,","place":["Shanghai, China, 200438"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhan","sequence":"additional","affiliation":[{"name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , , ,","place":["Shanghai, China, 200092"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8870-3637","authenticated-orcid":true,"given":"Defan","family":"Yao","sequence":"additional","affiliation":[{"name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , , ,","place":["Shanghai, China, 200092"]},{"name":"Shanghai Jiao Tong University School of Medicine , , ,","place":["Shanghai, China, 200025"]},{"name":"Shanghai University of Sport , ,","place":["Shanghai, China, 200438"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9529-4870","authenticated-orcid":true,"given":"Dengbin","family":"Wang","sequence":"additional","affiliation":[{"name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , , ,","place":["Shanghai, China, 200092"]},{"name":"Shanghai Jiao Tong University School of Medicine , , ,","place":["Shanghai, China, 200025"]},{"name":"Shanghai University of Sport , ,","place":["Shanghai, China, 200438"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"issue":"2","key":"2026102301071133600_cit1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"2026102301071133600_cit2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"2026102301071133600_cit3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ccell.2025.01.007","article-title":"Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer","volume":"43","author":"Zhang","year":"2025","journal-title":"Cancer Cell"},{"key":"2026102301071133600_cit4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217865","article-title":"The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): Emerging therapeutic opportunities","volume":"628","author":"Sabit","year":"2025","journal-title":"Cancer Lett."},{"issue":"1","key":"2026102301071133600_cit5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s40364-024-00714-6","article-title":"Tumor microenvironment and immunotherapy for triple-negative breast cancer","volume":"12","author":"Guo","year":"2024","journal-title":"Biomark. Res."},{"issue":"12","key":"2026102301071133600_cit6","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1021\/acssensors.2c02129","article-title":"Acoustic-Based Theranostic Probes Activated by Tumor Microenvironment for Accurate Tumor Diagnosis and Assisted Tumor Therapy","volume":"7","author":"Tian","year":"2022","journal-title":"ACS Sens."},{"issue":"3","key":"2026102301071133600_cit7","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"issue":"3","key":"2026102301071133600_cit8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nrclinonc.2016.195","article-title":"RECIST - learning from the past to build the future","volume":"14","author":"Liti\u00e8re","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"2026102301071133600_cit9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(23)00639-3","article-title":"Developing therapies for triple-negative breast cancer subtypes","volume":"25","author":"Okines","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026102301071133600_cit10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jconrel.2023.02.040","article-title":"Reactive oxygen species-powered cancer immunotherapy: Current status and challenges","volume":"356","author":"He","year":"2023","journal-title":"J. Control. Release"},{"issue":"9","key":"2026102301071133600_cit11","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1021\/acssensors.3c01203","article-title":"Smart Nanoplatform for Visualizing Hydrogen Sulfide and Amplifying Oxidative Stress to Tumor Apoptosis","volume":"8","author":"Chen","year":"2023","journal-title":"ACS Sens."},{"issue":"1","key":"2026102301071133600_cit12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-022-01304-4","article-title":"Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"22","key":"2026102301071133600_cit13","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202400809","article-title":"Emerging Chemodynamic Nanotherapeutics for Cancer Treatment","volume":"13","author":"Sun","year":"2024","journal-title":"Adv. Healthc. Mater."},{"issue":"21","key":"2026102301071133600_cit14","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202300191","article-title":"ROS Scavenging Nanozyme Modulates Immunosuppression for Sensitized Cancer Immunotherapy","volume":"12","author":"Mo","year":"2023","journal-title":"Adv. Healthc. Mater."},{"issue":"2","key":"2026102301071133600_cit15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ccell.2025.12.005","article-title":"Cancer cell death: Cell-autonomous and immunogenic dimensions","volume":"44","author":"Galluzzi","year":"2026","journal-title":"Cancer Cell"},{"key":"2026102301071133600_cit16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fimmu.2015.00187","article-title":"Combinatorial strategies for the induction of immunogenic cell death","volume":"6","author":"Bezu","year":"2015","journal-title":"Front. Immunol."},{"issue":"7637","key":"2026102301071133600_cit17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"7","key":"2026102301071133600_cit18","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"issue":"10","key":"2026102301071133600_cit19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103713","article-title":"Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer","volume":"9","author":"Quintana","year":"2024","journal-title":"ESMO Open"},{"key":"2026102301071133600_cit20","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.102078","article-title":"Transformable self-assembling peptide nanoplatforms with tumor microenvironment responsiveness for tumor stem cell suppression and immunomodulation","volume":"33","author":"Wei","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"1","key":"2026102301071133600_cit21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41523-020-00197-2","article-title":"Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies","volume":"6","author":"Marra","year":"2020","journal-title":"NPJ Breast Cancer"},{"issue":"7652","key":"2026102301071133600_cit22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"issue":"4","key":"2026102301071133600_cit23","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1158\/2159-8290.CD-23-1543","article-title":"Chemotherapy and the Extra-Tumor Immune Microenvironment: EXTRA-TIME","volume":"14","author":"Phan","year":"2024","journal-title":"Cancer Discov."},{"issue":"11","key":"2026102301071133600_cit24","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"2026102301071133600_cit25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/jmri.26058","article-title":"Imaging biomarkers in oncology: Basics and application to MRI","volume":"48","author":"Dregely","year":"2018","journal-title":"J. Magn. Reson. Imaging"},{"issue":"3","key":"2026102301071133600_cit26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrclinonc.2016.162","article-title":"Imaging biomarker roadmap for cancer studies","volume":"14","author":"O'Connor","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026102301071133600_cit27","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.101386","article-title":"Orchestrating cancer therapy: Recent advances in nanoplatforms harmonize immunotherapy with multifaceted treatments","volume":"30","author":"Xu","year":"2025","journal-title":"Mater. Today Bio"},{"key":"2026102301071133600_cit28","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114320","article-title":"Molecular imaging nanoprobes for theranostic applications","volume":"186","author":"He","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"2026102301071133600_cit29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s43586-024-00301-x","article-title":"Near-infrared II fluorescence imaging","volume":"4","author":"Schmidt","year":"2024","journal-title":"Nat. Rev. Methods Primers"},{"issue":"1","key":"2026102301071133600_cit30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41392-023-01366-y","article-title":"Molecular and functional imaging in cancer-targeted therapy: current applications and future directions","volume":"8","author":"Bai","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"2026102301071133600_cit31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.addr.2020.06.012","article-title":"Near-infrared fluorescence imaging in immunotherapy","volume":"167","author":"Ji","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"Suppl 6","key":"2026102301071133600_cit32","doi-asserted-by":"publisher","first-page":"vi23","DOI":"10.1093\/annonc\/mds191","article-title":"Imaging of triple-negative breast cancer","volume":"23","author":"Dogan","year":"2012","journal-title":"Ann. Oncol."},{"issue":"7","key":"2026102301071133600_cit33","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1021\/acs.analchem.7b00043","article-title":"Preparation and Practical Applications of 2\u2032,7\u2032-Dichlorodihydrofluorescein in Redox Assays","volume":"89","author":"Reiniers","year":"2017","journal-title":"Anal. Chem."},{"issue":"6","key":"2026102301071133600_cit34","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review","volume":"234","author":"Farhood","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"2026102301071133600_cit35","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","article-title":"Ki67 in breast cancer: prognostic and predictive potential","volume":"11","author":"Yerushalmi","year":"2010","journal-title":"Lancet Oncol."},{"issue":"1","key":"2026102301071133600_cit36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12943-024-02172-y","article-title":"Mechanisms and cross-talk of regulated cell death and their epigenetic modifications in tumor progression","volume":"23","author":"He","year":"2024","journal-title":"Mol. Cancer"},{"key":"2026102301071133600_cit37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1600-065X.2007.00531.x","article-title":"Convergence of immunoreceptor and integrin signaling","volume":"218","author":"Abram","year":"2007","journal-title":"Immunol. Rev."}],"container-title":["ACS Sensors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acssensors.6c03428","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/ascefj\/article-pdf\/doi\/10.1021\/acssensors.6c03428\/68809671\/se-2026-03428b.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/ascefj\/article-pdf\/doi\/10.1021\/acssensors.6c03428\/68809671\/se-2026-03428b.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:11:43Z","timestamp":1792743103000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/ascefj\/article\/11\/10\/9694\/5448422\/PD-L1-Targeted-and-ROS-Responsive-Nanoplatform-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,9]]},"published-print":{"date-parts":[[2026,10,23]]}},"URL":"https:\/\/doi.org\/10.1021\/acssensors.6c03428","relation":{},"ISSN":["2379-3694"],"issn-type":[{"value":"2379-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]}}}